benefits of glp 1 agonists Do The GLP-1 Drugs OutWeigh the Negatives? GLP-1 receptor agonists show promise
Description
[DOI] [PubMed] [Google Scholar] Stopher D
Weaver RE, Donnelly D, Wabitsch M, Grant PJ, Balmforth AJ
p = 0.022), especially in patients at high CV risk (age 65 years, T2D duration 10 years and BMI 30 kg/m 2 ), but not the other DPP-4is, suggesting a differential effect of each DPP-4 inhibitor on the risk of HF [151]
Ozempic and Mounjaro are brand names used for those with diabetes
Impact of substitution registry on receptor-activation profiles of backbone-modified glucagon-like peptide-1 analogues
